ArticleCancer science2016

Preclinical and first-in-human phase I studies of KW-2450, an oral tyrosine kinase inhibitor with insulin-like growth factor receptor-1/insulin receptor selectivity.

Gary K Schwartz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.